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Abstract  
Background 
Risk prediction after myocardial infarction is often complex in older patients. The Global 
Registry of Acute Coronary Events (GRACE) model includes clinical parameters and age, but 
not frailty. We hypothesised that frailty would enhance the prognostic properties of GRACE. 
Methods 
We performed a prospective observational cohort study in two independent cardiology units: 
the Royal Infirmary of Edinburgh, UK (primary cohort) and the South Yorkshire 
Cardiothoracic Centre, Sheffield, UK (external validation). The study sample included 198 
patients ≥65 years old hospitalised with type 1 myocardial infarction (primary cohort) and 96 
patients ≥65 years old undergoing cardiac catheterisation for myocardial infarction (external 
validation). Frailty was assessed using the Clinical Frailty Scale (CFS). The GRACE 2.0 
estimated risk of 12-month mortality, Charlson comorbidity index and Karnofsky disability 
scale were also determined for each patient. 
Results 
Forty (20%) patients were frail (CFS ≥5). These individuals had greater comorbidity, 
functional impairment and a higher risk of death at 12 months (49% vs. 9% in non-frail 
patients, p<0.001). The hazard of 12-month all-cause mortality nearly doubled per point 
increase in CFS after adjustment for age, sex and comorbidity (Hazard Ratio [HR] 1.90, 95% 
CI 1.47–2.44, p<0.001). The CFS had good discrimination for mortality by Receiver 
Operating Characteristic (ROC) curve analysis (Area Under the Curve [AUC] 0.81, 95% CI 
0.72–0.89) and enhanced the GRACE estimate (AUC 0.86 vs. 0.80 without CFS, p=0.04). At 
existing GRACE thresholds, the CFS resulted in a Net Reclassification Improvement (NRI) of 
0.44 (95% CI 0.28–0.60, p<0.001), largely through reductions in risk estimates amongst non-
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frail patients. Similar findings were observed in the external validation cohort (NRI 0.46, 95% 
CI 0.23–0.69, p<0.001). 
Conclusions 
The GRACE score overestimated mortality risk after myocardial infarction in these cohorts of 
older patients. The CFS is a simple guided frailty tool that may enhance prediction in this 
setting. These findings merit evaluation in larger cohorts of unselected patients.  
Clinical Trial Registration: clinicaltrials.gov; NCT02302014 (November 26th 2014, 
retrospectively registered) 
 
Keywords: frailty, risk prediction, myocardial infarction, acute coronary syndrome 
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Background 
The population admitted to hospital following myocardial infarction is ageing. Advances in 
patient care have reduced age-specific mortality rates in developed countries, but this effect is 
offset by an expanding older population.1,2 However, clinical trials in acute coronary 
syndrome have consistently failed to represent older adults, limiting the generalizability of 
findings to this age group.3 The Global Registry of Acute Coronary Events (GRACE) sought 
to provide a larger and more representative sample, demonstrating significant disparities in 
the management and in-hospital outcomes for the oldest patients with myocardial 
infarction.4,5 These data have generated GRACE risk estimates which include age amongst 
other clinical parameters to predict outcomes following myocardial infarction.6,7  
 
However, it is recognized increasingly that frailty, as a metric of depleted physiological 
reserves, better reflects biological age in older adults.8 Frailty is three-fold more common in 
older people with cardiovascular disease9 and these individuals experience double the 
mortality risk of fitter people independent of age or comorbidity.10 For risk prediction, gait 
speed has been shown to add value to Framingham risk scores of patients with ST-segment 
elevation myocardial infarction.11 Similarly in patients with non-ST-segment elevation 
infarctions, the physical frailty phenotype independently predicted major cardiovascular 
events beyond the GRACE score in the TRILOGY ACS randomised control trial comparing 
antiplatelet strategies.12 Similar reports of the effect of frailty on GRACE risk estimates come 
from studies using physical measures that necessitate additional patient testing.13  
 
The Clinical Frailty Scale (CFS) is a brief guided tool to assess frailty in hospital settings 
without specialist equipment.14 It has been widely used to identify older patients at risk of 
poorer outcomes.15 Although it does not require additional equipment or physical measures, 
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the CFS is a precise frailty tool, using specific descriptors of patient symptoms and activity. 
Our objective was to test the performance of the CFS in an older population with myocardial 
infarction. We hypothesised that addition of this simple frailty measure would improve the 
prognostic properties of the GRACE score. 
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Methods 
Study design and participants 
Patients aged ≥65 years old were assessed prospectively within the screening registry of a 
phase II randomized controlled trial of future care planning in advanced heart disease at the 
Royal Infirmary of Edinburgh between October 2013 and September 2014 (NCT 
02302014).16 Patients with moderate/severe dementia or other barriers to informed consent 
were excluded. All patients in the registry with a clinical diagnosis of type 1 myocardial 
infarction were included, except the fifty patients who underwent a tailored intervention in the 
phase II study. The registry protocol was approved by a local research ethics committee 
(reference 12/SS/0223) and the study was conducted in collaboration with a UKCRC (UK 
Clinical Research Collaboration) registered Clinical Trials Unit.   
 
Frailty measure 
The CFS is a structured scale of descriptors to guide selection between nine levels ranging 
from “very fit: 1” to “terminally ill: 9”. Frailty may be assessed as a continuum, but is 
considered present at a score ≥5 (Supplementary Figure 1).14 Assessment criteria include 
activity, symptoms and assistance usually required with personal activities of daily living (e.g. 
washing and toileting), and instrumental tasks necessary for independent community living 
(e.g. managing finances and medications). Clinical nursing staff completed the CFS for each 
study patient based on their professional assessment and any documentation of premorbid 
functional status. Nurses received training in the use of the tool from the research team. 
 
GRACE risk estimate 
The GRACE estimated risk of 12-month mortality after myocardial infarction was determined 
using the online version 2.0 calculator 
 7 
 
(http://www.gracescore.org/website/WebVersion.aspx).7 Clinical and biochemical measures 
required for the score (heart rate, systolic blood pressure, Killip class, creatinine, cardiac 
troponin and electrocardiogram changes) were taken from the time of initial presentation with 
cardiac symptoms. The tool assigns categories based on the calculated risk: low (<4% 
estimated 12-month mortality risk), medium (4−12%) and high (>12%) risk. 
 
Comorbidity and functional measures 
Comorbidity was measured using the Charlson comorbidity index, with a higher score 
indicating greater comorbidity.17 Functional status and disability were recorded on the 
Karnofsky scale, with increasing dependency indicated by a lower score in the range of 0–
100.18 Research staff completed these scales using all available paper and electronic health 
records (TrakCare; InterSystems Corporation, Cambridge, MA, USA) together with patient or 
family history.  
 
Outcomes 
Electronic health records were used to determine the primary endpoint of all-cause mortality 
in the 12 months following index admission. Secondary outcomes were length of index 
hospital stay, completion of cardiac catheterization (with or without percutaneous coronary 
intervention), hospital readmissions within 12 months and attendance at cardiac rehabililation.  
 
External validation cohort 
Findings from the primary analysis were also tested in an independent cohort, comprising 96 
patients aged ≥65 years old undergoing cardiac catheterization following myocardial 
infarction at the South Yorkshire Cardiothoracic Centre (Sheffield, UK), a tertiary referral 
centre for a population of 1.8 million people in the North of England. GRACE and CFS 
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scores were available for all participants. The recruitment and data collection within this 
cohort has been previously described in detail.19,20 
 
Statistical analysis 
Continuous data are presented as means ± SD or median ± IQR and where appropriate 
compared by Student’s t-test, Mann-Whitney U-test or Analysis of Variance (ANOVA). 
Categorical data are presented as absolute numbers and percentages and compared by Chi-
squared test. Logistic, linear and Cox proportional hazards regression modelling were used to 
determine predictors of the primary and secondary outcomes. Differences between frailty 
groups in survival analysis were assessed by log rank test. Receiver operating characteristic 
(ROC) curve analysis was performed by standard methods for discrimination of 12-month 
mortality. Model fit was assessed by Akaike and Bayesian Information Criteria (AIC and BIC 
respectively). Coefficients derived from a multiple logistic regression model including both 
GRACE and CFS scores from the study population were applied to the exernal validation 
cohort. 
 
To calculate Net Reclassification Improvement (NRI), each patient was assigned one of three 
risk categories from the GRACE calculator output (low, medium or high risk). Using the 
multiple logistic regression model including both GRACE and CFS, all patients were 
reclassified and reported against the same GRACE risk thresholds. The analysis was 
performed separately in those who died and survived to assess the net reclassification of 
patients, thereby accounting for both appropriate and inappropriate reclassifications. This was 
calculated as an unweighted or ‘dimensionless NRI’. All analyses were completed with R 
(version 3.3.3). NRI calculations were completed using the pROC package.21  
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Results 
The study population comprised 198 patients with type 1 myocardial infarction, the majority 
of whom were male (58%) and with a mean age of 79±6 years. Baseline characteristics are 
shown in Table 1. The external validation cohort consisted of 96 patients (61% male, mean 
age 74±6 years, Supplementary Table 1). Baseline measures and follow-up to 12 months 
was completed in all patients. 
 
The CFS identifies a high-risk group of patients with poorer outcomes 
The CFS identified 40 (20%) patients with frailty defined by a CFS score ≥5 (Figure 1). 
Using this established CFS threshold, frail patients were older, more often female and 
experienced greater comorbidity (mean Charlson Comorbidity Index 3.9±2.2 vs. 2.6±1.6 in 
those with CFS ≤4, p<0.001, Table 1). There were notably higher levels of previous heart 
failure, chronic kidney disease, respiratory illness and dementia amongst frail patients. Age, 
comorbidity, functional impairment and GRACE estimated mortality risk increased with 
higher CFS scores (p<0.001 for all, Figure 1). Overall, GRACE estimated 12-month 
mortality was greater in frail patients (28% vs. 16% in those with CFS ≤4, p<0.001).  
 
Frail patients were prescribed more medications before hospital admission (10.5±2.9 vs. 
8.9±3.1 with CFS ≤4, p=0.003). Index hospitalization was also longer (11 days [IQR 5–24] 
vs. 4 days [IQR 3–7] with CFS ≤4, p<0.001), but cardiac catheterization was undertaken less 
frequently in frail patients (33% vs. 81% with CFS ≤4, p<0.001, Table 2). Observed mortality 
was higher in frail patients, with 15% dying during the index hospitalization and nearly half 
by 12 months (48% vs. 9% with CFS ≤4, p<0.001). Thus, frailty was associated with 
spending a shorter period alive and out of hospital in the year following index hospitalization 
(mean 229±137 vs. 329±68 days with CFS ≤4, p<0.001). In those that survived to hospital 
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discharge, no patient with CFS ≥5 attended cardiac rehabilitation. In non-frail patients, each 
point increase in CFS was associated with a reduced likelihood of attendance at rehabiliation, 
after adjustment for age, sex and baseline comorbidity (adjusted odds ratio [OR] 0.59, 95% 
confidence intervals [CI] 0.42–0.80 per unit increase in CFS, p=0.001). However, the CFS did 
not predict hospital readmissions over the 12 months after index admission following 
adjustment (adjusted HR 1.10 (0.86–1.40), p=0.44). 
 
The CFS is an independent predictor of mortality risk  
Considering frailty as a continuous variable, each point increase in CFS score predicted a 
doubling of the hazard of 12-month mortality (HR 1.98, 95% CI 1.60–2.44, p<0.001), with 
the effect minimally attenuated after adjustment for age, sex and comorbidity (adjusted HR 
1.90, 95% CI 1.47–2.44, p<0.001, Table 2). The relationship between CFS and mortality 
remained independent following adjustment for the GRACE score (adjusted HR 1.72, 95% CI 
1.37–2.16 per unit increase in CFS, p<0.001). Similarly the Karnofsky score remained an 
independent predictor of mortality beyond GRACE (adjusted HR 0.96, 95% CI 0.94–0.98 per 
unit increase, p<0.001), but the Charlson comorbidity index did not (adjusted HR 1.21, 95% 
CI 0.99–1.46, p=0.06). By linear regression modelling, the number of days alive and out of 
hospital in the 12 months after index admission decreased by 25 days with each point increase 
in CFS (95% CI 18–33 days, p<0.001).  
 
Using the CFS to divide the population into non-frail (CFS 1-3), vulnerable or mildly frail 
(CFS 4-5) and moderate to severely frail (CFS 6-9) patients demonstrated separation of 
survival curves throughout the 12 months following index hospitalization (log rank test 
p<0.001, Figure 2).  
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Addition of the CFS improves discrimination of the GRACE risk estimate 
The area under the ROC curve (AUC) for an outcome of 12-month mortality after myocardial 
infarction was 0.80 (95% CI 0.71–0.88) for the GRACE score and 0.81 (95% CI 0.72–0.89) 
for the CFS. These were stronger discriminators than either the Charlson comorbidity index 
(AUC 0.68, 95% CI 0.58–0.78) or Karnofsy score (AUC 0.76, 95% CI 0.68–0.87, 
Supplementary Figure 2). Addition of the CFS to GRACE improved the AUC to 0.86 (95% 
CI 0.78–0.92), which represented a significant gain by DeLong testing (p=0.04, Figure 3). 
Both the AIC and BIC were lower in the model including the CFS score implying improved 
model fit.  
 
Addition of CFS to GRACE results in net reclassification improvement 
By GRACE estimation, high-risk status (>12% risk of 12-month mortality) was applied to 
112 (57%) patients, medium risk (4-12% risk) to 81 (41%) patients and low risk (<4% risk) to 
5 (3%) patients. Within the high-risk cohort, survival curves demonstrated continued 
separation by frailty status (log-rank test p<0.001, Supplementary Figure 3). Addition of the 
CFS in a multiple logistic regression model with the GRACE score resulted in a NRI of 0.44 
(95% CI 0.28–0.60, p<0.001), with the majority of reclassification events downgrading 
estimated risk (Supplementary Table 2). Amongst all patients who were still alive at 12 
months, 97 (59%) moved to a lower GRACE risk category with the updated model.  
 
Expected and observed mortality 
Across the study population, the predicted 12-month mortality by GRACE estimate was 
18.5%, which compared to an observed mortality of 16.7%. Dividing the population by CFS 
frailty status identified an overestimation of risk amongst patients with CFS ≤4 (16.2% 
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predicted vs. 8.9% observed), and an underestimation in frail patients (27.8% predicted vs. 
47.5% observed with CFS≥5, Supplementary Table 3). Formal calibration testing was not 
performed due to sample size.  
 
External validation 
In the external validation cohort, 27 (28%) patients were frail (CFS ≥5). There were 14 (15%) 
deaths within 12 months. After applying the multiple logistic regression model coefficients 
derived in the main study to this external validation cohort, the AUC for 12-month mortality 
was 0.75 (95% CI 0.60–0.87), although this was not a significant improvement on GRACE 
alone (p=0.40, Supplementary Figure 4). By NRI, applying the main study model improved 
classification in the validation cohort (0.46, 95% CI 0.23–0.69, p<0.001), once more through 
reductions in estimated risk using the model including CFS (Supplementary Table 4). 
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Discussion 
We have studied the utility of a simple frailty measure for risk prediction in older patients 
after myocardial infarction and have made a number of important observations. First, the 
GRACE tool overestimated 12-month mortality risk in our study population. Second, a 
guided frailty tool could be incorporated into routine clinical care to identify patients at high 
risk of poor outcomes. Third, the Clinical Frailty Scale was an independent predictor of 
mortality in an older myocardial infarction population and added significant discrimation to 
the GRACE 12-month mortality estimate. Finally, frailty reclassified mortality risk in nearly 
half of this population, largely through identification of older but fitter individuals. This 
simple measure of frailty has potential to improve risk assessment in the large population of 
older patients recovering from myocardial infarction. 
 
There are a number of strengths to our study. Frailty assessment was performed by clinical 
nursing staff using existing clinical data and without any specialist equipment. This approach 
would appear feasible for inclusion into the routine care of older cardiology patients based on 
our experience in a busy tertiary referral centre. In contrast to other studies22,23, we have not 
focussed solely on short-term risk estimation and have directly assessed frailty against an 
existing and widely used clinical tool. Further, we have undertaken external validation 
suggesting wider applicability of these findings, although this would benefit from larger 
validation studies. With advances in cardiac care, the majority of even the oldest patients 
survive an acute infarct.24 The attention of risk prediction after myocardial infarction has 
therefore shifted from immediate survival to recovery, rehabilitation and future risk-
stratification. Identification of vulnerability to poor outcomes could guide tailored cardiac 
rehabilitation, follow-up and future intervention strategies.  
 
 14 
 
It may be surprising that most reclassification gains occurred by downgrading the estimated 
GRACE risk in robust patients. This challenges preconceptions that frailty assessment only 
adds value in those nearing death; resilience in fitter older patients may be equally 
informative. However, at the other end of this spectrum, it is striking that half of the patients 
identified as frail by CFS assessment had died within 12 months of myocardial infarction. 
Frailty assessment offers the potential for future care planning in this targeted population, 
which we have previously shown to be feasible and acceptable in our phase II study.16 
Individualized decision-making including frailty could therefore increase clinician confidence 
in the management of patients across the range of vulnerability from low to high risk. Such an 
approach is the antithesis of ageism, and may assist in targeting increasingly complex 
interventions towards to those most likely to experience benefit.25 
 
Our findings may reflect excessive reliance on age in current risk determination. At a 
population level there is no doubt that ageing increases the risk of almost all harmful 
outcomes, but chronological age fails to capture individual differences. At its core, frailty 
exposes the variation in ageing trajectories between individuals.8 In this study, age was not 
independently predictive of any outcome once frailty was included in modelling. It is however 
important to recognize that the GRACE estimation, which includes age as a key variable, 
peformed well in the discrimination of 12-month mortality in the study population, but worth 
acknowledging that frailty could improve this further and provide net reclassification benefit. 
Such improvements in the discrimination of existing risk scores are rarely achieved by new 
biomarkers26 and this finding merits further evaluation in larger cohorts, or perhaps in future 
iterations of the GRACE tool.  
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The 2015 European Society of Cardiology guidelines recommend use of the GRACE 2.0 
calculator to assess patient risk after myocardial infarction, stating that the value of such tools 
is “undisputed”. However, the guidelines acknowledge that “the impact of risk score 
implementation on patient outcomes has not been adequately investigated”.27 The 
complexities of managing frail patients are recognized, particularly with regard to invasive 
strategies and adjusted dose regimes for antiplatelets, beta-blockers and ACE-inhibitors. In 
our study no frail patients attended cardiac rehabilitation, in keeping with referral patterns 
observed elsewhere.28 This is despite increasing evidence in favour of structured physical 
activity programmes amongst individuals living with frailty.29 The European Association of 
Preventative Cardiology have recently identified the pressing clinical need for further 
research into the area of frailty and cardiac rehabilitation.30 No specific frailty tool is 
recommended by these guidelines, which in part reflects a lack of consensus in the broader 
frailty literature. A recent systematic review identified reports of 67 different frailty tools, of 
which the CFS is one of the most highly cited.15 
 
Other recent guidelines for the management for older patients have focussed on 
multimorbidity, such as from the National Institute for Health and Care Excellence (NICE).31 
However, the Charlson comorbidity index did not add to the GRACE estimation in our study, 
suggesting that simplistic counts of comorbidity may be less important than assessing the 
functional manifestations of these conditions. We have demonstrated that the Karnofsky 
performance scale was an independent predictor of mortality beyond GRACE, although 
discrimination was not as strong as with the CFS. It is possible that such functional and 
disability scales may add further objectivity to the classification of frailty. 
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Our study has some limitations. The study population was recruited for potential selection 
into a study of future care planning. An age cutoff was chosen to enrich for the frailty 
measure, but this limited the identification of younger patients with impairments. The study 
cohort was therefore likely to have been at higher risk than a general, older cardiology 
population. Despite this, only 20% of our study population were graded with a CFS score ≥5, 
which represents a realistic proportion for additional intervention such as future care 
planning. The CFS did not independently predict hospital readmission, but this may be related 
to competing mortality risk amongst frail patients. It is critical that an effective frailty 
measure does not saturate in the target population, as this would lack any clinical utility 
beyond age. The distribution of CFS scores across our study was significantly less frail than 
in the Canadian older community-dwelling population in which it was first described.14 This 
may be due to a younger but more medically comorbid sample hospitalized with myocardial 
infarction, but may also reflect our limited sample size. Although we undertook external 
validation this was also performed in a small cohort.  
 
Conclusions 
In conclusion we have demonstrated the effectiveness of a simple frailty tool in the 
assessment of older patients after myocardial infarction. The CFS could be included in the 
routine clinical assessment of cardiology patients, providing improved discrimination of the 
existing GRACE estimate for 12-month mortality. Risk assessment including frailty has 
potential to enhance individualized decisions in cardiac patients. These findings merit 
evaluation in larger and unselected cohorts. 
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Figure Legends 
 
Figure 1: Frequency histogram for the distribution of Clinical Frailty Scale scores (range 1–
9) in the study population. Appended table shows the mean age, GRACE 12-month mortality 
risk estimation, Charlson comorbidity index and Karnofsky scale score in the study sample 
with each CFS score. By ANOVA, each of these measures demonstrated a significant change 
with increasing CFS scores (all p<0.001). 
 
Figure 2: Kaplan-Meier survival plot for the year following index hospital admission, 
stratified by frailty status. Frailty defined by CFS thresholds for not frail (CFS 1–3), 
vulnerable or mild frailty (CFS 4–5) and moderate to severe frailty (CFS 5–9). Log rank test 
for difference p<0.001. 
 
Figure 3: ROC curve for the prediction of 12-month mortality by GRACE score and with 
addition of CFS in multiple logistic regression modelling. AUC = area under the curve; AIK= 
Akaike Information Criteria; BIC = Bayesian Information Criteria. 
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Table 1: Baseline characteristics by frailty status 
 
All patients 
 
(n=198) 
Not frail  
(CFS 1-4) 
(n=158) 
Frail 
(CFS 5-9) 
(n=40) 
Age, years (mean, SD) 79 (6) 78 (6) 83 (7) 
Male 115 (58) 99 (63) 16 (40) 
    
Primary diagnosis    
Non-ST segment elevation myocardial infarction 151 (76) 122 (77) 29 (73) 
ST-segment elevation myocardial infarction 47 (24) 36 (23) 11 (28) 
    
Past medical history    
Heart failure  36 (18) 21 (13) 15 (38) 
Stroke 35 (18) 25 (16) 10 (25) 
Diabetes mellitus 35 (18) 32 (20) 3 (8) 
Chronic kidney disease (stage III or worse) 45 (23) 30 (19) 15 (38) 
Peripheral vascular disease 28 (14) 21 (13) 7 (18) 
Chronic respiratory disease 39 (20) 25 (16) 14 (35) 
Dementia 14 (7) 7 (4) 7 (18) 
Current or ex-smoker 118 (60) 96 (61) 22 (55) 
    
Medications at recruitment    
Total number prescribed drugs (mean, SD) 9.2 (3.1) 8.9 (3.1) 10.5 (2.9) 
Aspirin 178 (90) 144 (91) 34 (85) 
Clopidogrel 183 (92) 145 (92) 38 (95) 
ACE-inhibitor or ARB 127 (64) 113 (72) 14 (35) 
Diuretic 80 (40) 57 (36) 23 (58) 
Beta-blocker 118 (60) 98 (62) 20 (50) 
Statin 155 (78) 132 (84) 23 (58) 
Oral anticoagulant 26 (13) 22 (14) 4 (10) 
    
Laboratory measures    
Haemoglobin, g/L (mean, SD) 13.1 (1.8) 13.1 (1.8) 12.7 (2.0) 
Creatinine, µmol/L (mean, SD)  104 (45) 101 (39) 119 (62) 
Estimated GFR, ml/min/1.73m2 (mean, SD) 62 (24) 65 (23) 54 (24) 
    
Risk and functional measures    
GRACE 2 12-month mortality (mean, SD) 18.5 (13.2) 16.2 (11.7) 27.8 (15.0) 
Charlson comorbidity index (mean, SD) 2.9 (1.8) 2.6 (1.6) 3.9 (2.2) 
Karnofsky scale score (mean, SD) 78.5 (17.1) 84.6 (11.8) 54.5 (13.0) 
Values are number (%) unless specified 
Abbreviations: CFS = Clinical Frailty Scale; GFR = glomerular filtration rate (calculated by the Modification of Diet in Renal Disease 
equation); ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; GRACE = Global Registry for Acute Coronary 
Events. 
Not frail defined by CFS 1-4 (very fit, well, managing well, vulnerable) and frail by CFS 5-9 (mildly frail, moderately frail, severely frail, very 
severely frail, terminally ill)  
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Table 2: Outcomes by frailty from multivariate regression modelling 
 
 All patients 
(n=198) 
Not frail 
(CFS 1-4) 
(n=158) 
Frail 
(CFS 5-9) 
(n=40) 
Unadjusted RR per 
unit increase in CFS p-value 
Adjusted RR per unit 
increase in CFS* p-value 
Index hospital admission outcome        
Cardiac catheterization  141 (71) 128 (81) 13 (33) 0.46 (0.35–0.58) <0.001 0.53 (0.40–0.70) <0.001 
Dead 10 (5) 4 (3) 6 (15) 1.98 (1.60–2.44) <0.001 1.90 (1.47–2.44) <0.001 
        
At 12 months        
Attended cardiac rehabilitation+ 62 (33) 62 (40) 0 (0) 0.49 (0.36–0.64) <0.001 0.59 (0.42–0.80) 0.001 
Readmitted+ 46 (24) 34 (22) 12 (35) 1.39 (1.17–1.67) <0.001 1.10 (0.86–1.40) 0.44 
Dead 33 (17) 14 (9) 19 (48) 1.98 (1.60–2.44) <0.001 1.90 (1.47–2.44) <0.001 
Outcomes presented by frailty status as numbers (%). Modelling is Cox proportional hazards for death and readmission (producing a hazard ratio), and logistic regression for cardiac catheterization 
and cardiac rehabilitation (producing an odds ratio). In all cases, frailty is considered as a continuous variable. Each risk ratio (hazard ratio or odds ratio) presented as risk change per unit increase in 
CFS (from 1-9) with 95% confidence intervals. 
*Adjusted for age, sex and Charlson Comorbidity Index score 
+In those who survived to discharge (n=188; not frail n=154; frail n=34). 
 
 
